Study #2023-0962
A phase 3, randomized, open-label study to investigate the efficacy and safety of ITK inhibitor Soquelitinib versus physician's choice standard of care treatment (Selected Single Agent) in participants with Relapsed/Refractory peripheral T-cell Lymphoma not otherwise specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Soquelitinib, Belinostat, Pralatrexate
Description
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell
Study phase:
Phase III
Physician name:
Swaminathan Iyer
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.